Suliqua

Suliqua is a prescription medication developed by Sanofi, a French multinational pharmaceutical company. It is a combination of insulin glargine, a long-acting insulin, and lixisenatide, a GLP-1 receptor agonist, used to improve glycemic control in adults with type 2 diabetes. Suliqua is administered via a pre-filled pen and is available in multiple countries, including the United States and European Union. Sanofi, headquartered in Paris, France, is the ultimate owner of the Suliqua brand, with no known subsidiaries owning the brand locally.